German med schools perfectly OK with pharma-rep visits and gifts

German med school deans aren't too concerned with pharma reps swaying their students' future prescription habits, according to a recent survey. The findings: Only two of 30 responding universities had created guidelines for staff and students on dealing with pharma companies, and only 6 said they desired those guidelines. "That's a remarkably low number," one study conductor said. "We're behind the U.S. on this by 10 to 15 years." More

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.